Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial

BACKGROUND: LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung. We report the final overall survival (OS) and safety analyses of LUX-Lung 8 and investigate the characteri...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:EClinicalMedicine
Autores principales: Goss, Glenwood D, Cobo, Manuel, Lu, Shun, Syrigos, Konstantinos, Lee, Ki Hyeong, Göker, Erdem, Georgoulias, Vassilis, Isla, Dolores, Morabito, Alessandro, Min, Young J, Ardizzoni, Andrea, Bender, Shaun, Cseh, Agnieszka, Felip, Enriqueta
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8225678/
https://ncbi.nlm.nih.gov/pubmed/34195574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100940
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares